Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.
Organogenesis Holdings Inc. (Nasdaq: ORGO) is a pioneering company in the field of regenerative medicine. Headquartered in Canton, Massachusetts, Organogenesis offers a diverse portfolio of bioactive and acellular biomaterial products, primarily targeting the Advanced Wound Care and Surgical & Sports Medicine markets. The company's innovative solutions cater to a wide range of patients with repair and regenerative needs.
The company's core products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, and Dermagraft, which are designed to improve patient outcomes while reducing overall healthcare costs. Organogenesis is recognized for its advancements in both orthopedics and spine treatments, reflecting its commitment to addressing unmet medical needs through cutting-edge research and development.
In recent news, Organogenesis has reported significant milestones and achievements. The company announced that its Phase 3 randomized control trial evaluating ReNu, a cryopreserved amniotic suspension allograft for knee osteoarthritis (OA), met its primary endpoint, demonstrating a significant reduction in knee OA pain. This achievement is poised to introduce new non-surgical treatment options for OA patients, potentially opening a significant market opportunity for Organogenesis.
The company has also faced challenges. Its third-quarter revenue was impacted by local coverage determination (LCD) issues, yet it managed to deliver substantial improvements in operating profitability and adjusted EBITDA. Organogenesis continues to build momentum with commercial support programs aimed at enhancing customer relationships and regaining lost accounts.
Financially, the company reported a net revenue of $99.7 million in the fourth quarter of 2023, reflecting a decrease from the previous year. Despite these hurdles, Organogenesis remains financially robust with $104.3 million in cash and equivalents as of December 2023. Its operating expenses have been carefully managed, showcasing a reduction in selling, general, and administrative expenses.
Looking ahead, Organogenesis has set optimistic projections for 2024, with anticipated revenue growth driven by new product launches and the continued demonstration of value to customers. The company is also planning to further engage with regulatory bodies to secure approvals and expand the clinical indications of its products.
Overall, Organogenesis Holdings Inc. stands out for its commitment to innovation, patient care, and financial stability, making it a significant player in the regenerative medicine landscape. For more information, visit their official website.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported robust financial results for Q1 2021, with net revenue of $102.6 million, a 66% increase from Q1 2020's $61.7 million. Advanced Wound Care products drove this growth, reaching $90.7 million (up 77%). The company achieved a net income of $9.9 million, a significant turnaround from the $16.3 million loss in the prior year. Operating income improved to $12.6 million. Looking ahead, net revenue guidance for 2021 is set between $438 million and $454 million, projecting a 29% to 34% increase year-over-year.
Organogenesis Holdings Inc. (Nasdaq: ORGO) appointed Jon Giacomin to its Board of Directors, effective May 7, 2021, following Wayne Mackie's resignation on the same day. Giacomin brings nearly 30 years of healthcare experience, previously serving as CEO of U.S. Anesthesia Partners and Cardinal Health’s Medical Segment, which generated over $15 billion in revenue. This strategic leadership change aims to enhance the company’s growth potential as it continues to develop its regenerative medicine solutions in wound care and surgical markets.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has announced its participation as a Platinum Sponsor at the upcoming 2021 Symposium on Advanced Wound Care Spring. The company will showcase its advanced wound care product lines, including PuraPly® AM and Apligraf®, with a focus on clinical evidence supporting their efficacy. On May 14, a presentation titled 'Clinical Evidence Outlines the Need for Early Advanced Standard of Care' will discuss a pooled analysis of 434 wounds. Other research highlights include podium and video presentations on the effectiveness of various wound care solutions.
Organogenesis Holdings Inc. (Nasdaq: ORGO) will announce its first quarter fiscal year 2021 financial results after market close on May 10. A conference call is scheduled for the same day at 5:00 p.m. ET to discuss the results and provide corporate updates. Interested participants can join by dialing 866-795-3142, with international callers using 409-937-8908, and using access code 9199306. A live webcast will also be available on their investor relations website, with a replay accessible for two weeks following the call.
Organogenesis Holdings (Nasdaq: ORGO) reported Q4 2020 net revenue of $106.8 million, a 43% increase YoY, driven by strong sales in Advanced Wound Care, which rose 48% to $93.6 million. Net income surged to $18.5 million from a loss of $4.4 million in Q4 2019. For FY 2020, total revenue reached $338.3 million, up 30%, with net income of $17.9 million. Looking ahead, the company expects FY 2021 revenue between $390 million and $405 million, reflecting a projected 15-20% growth.
Organogenesis Holdings (Nasdaq: ORGO) appointed David C. Francisco as Chief Financial Officer, effective February 15, 2021. Francisco, who has over 25 years of finance experience, previously held leadership roles at PerkinElmer, where he oversaw significant revenue growth. CEO Gary Gillheeney expressed optimism about Francisco's strategic insights, aiming to enhance operational performance and profitability amid growth opportunities. However, the company has faced substantial losses and competitive pressures, making its future profitability uncertain.
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leader in regenerative medicine, has announced its participation in several upcoming investor conferences. These include the BTIG Virtual MedTech Conference on February 18 at 1:00 p.m. ET, the SVBLeerink Global Healthcare Conference on February 24 at 8:40 a.m. ET, and the Oppenheimer Healthcare Conference on March 17 at 10:40 a.m. ET. Live audio webcasts will be available on the company's website, with archives accessible for 30 days post-conference.
Organogenesis Holdings Inc. (Nasdaq: ORGO) will announce its fourth quarter and fiscal year 2020 financial results on March 16, 2021, after market closure. A conference call will follow at 5:00 p.m. ET to discuss the financial outcomes and provide corporate updates. Interested participants can join by calling 866-795-3142 (international callers: 409-937-8908) and using access code 6766924. A live webcast will be available on the company's investor relations website, with a replay accessible for two weeks thereafter.
Organogenesis Holdings has initiated a pivotal Phase 3 clinical trial for ReNu®, a cryopreserved amniotic suspension allograft, targeting knee osteoarthritis treatment, with the first patient enrolled. The trial involves 474 subjects in a randomized controlled study comparing ReNu to a saline placebo. The primary endpoint will assess pain reduction over six months using the WOMAC index. The company's RMAT designation from the FDA supports expedited review processes, addressing a significant market demand as knee OA affects over 14 million Americans, with increasing knee replacement surgeries.
FAQ
What is the current stock price of Organogenesis Hldgs (ORGO)?
What is the market cap of Organogenesis Hldgs (ORGO)?
What is Organogenesis Holdings Inc.?
Where is Organogenesis Holdings Inc. headquartered?
What are some of the core products of Organogenesis?
What recent achievement has Organogenesis announced?
How did Organogenesis perform financially in the fourth quarter of 2023?
What are the future prospects for Organogenesis?
What markets does Organogenesis target?
What is the significance of ReNu in Organogenesis's portfolio?
How does Organogenesis contribute to healthcare cost reduction?
Where can more information about Organogenesis be found?
